Expert Opinion on Drug Metabolism & Toxicology

Papers
(The H4-Index of Expert Opinion on Drug Metabolism & Toxicology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Probing the mechanism of reduced in vivo potency of insulin detemir105
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update52
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects52
Pharmacotherapy in kidney disease: what it takes to move from general guidance to specific recommendations to stratified subgroups of patients - the tale of autosomal dominant polycystic kidney diseas45
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis44
Tirabrutinib–anthracycline interactions in the brain tumor microenvironment: a focus on metabolic inactivation and resistance36
The Central Role of Cytochrome P450 Reductase (CPR) in Hyperoxic Lung Injury34
Hormones, microbes, and PrEP drugs in the female genital tract27
Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata26
Guidance for interactions between antiseizure medications26
Comorbidities and the right dose: antipsychotics25
Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury24
An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria24
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine23
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database22
Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis20
Bioactivity descriptors for in vivo toxicity prediction: now and the future19
Correction18
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer18
0.34758114814758